Novartis AG operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Novartis with three other
pharmaceutical manufacturers in Europe:
sales of 34.86 billion Euro [US$37.05 billion]
of which 85%
Roche Holding Aktiengesellschaft
(48.15 billion Swiss Francs [US$47.81 billion]
of which 78%
was Pharmaceuticals), and
based in Germany
(46.32 billion Euro [US$49.23 billion]
of which 30%
was Pharmaceuticals & Biological Products).
Novartis reported sales of 48.55 billion Swiss Francs (US$48.22 billion)
December of 2015.
decrease of 1.4%
versus 2014, when the company's sales were 49.25 billion Swiss Francs.
The sales level in 2015 was fairly close to the level five years ago: in 2010, Novartis had sales
of 52.68 billion Swiss Francs.
Contributing to the drop in overall sales was the 5.6% decline
in Alcon, from 10.02 billion Swiss Francs to 9.46 billion Swiss Francs.
There were also decreases in sales in
Pharmaceuticals (down 2.2% to 29.35 billion Swiss Francs)
Sandoz (down 2.5% to 8.83 billion Swiss Francs)